Akram Al-Makki
Overview
Explore the profile of Akram Al-Makki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Isreb M, Al-Makki A, Buatois E
N Engl J Med
. 2019 Sep;
381(11):1088.
PMID: 31509682
No abstract available.
12.
Yeboah K, Allspaw A, Al-Makki A, Shepler B
Clin Ther
. 2018 Sep;
40(9):1592-1595.
PMID: 30166053
Purpose: Several antihypertensive medications have been associated with various forms of sexual dysfunction. We present a case report of a premenopausal patient with hydralazine-associated amenorrhea. Methods: The Naranjo adverse drug...
13.
Albright T, Al-Makki A, Kalakeche R, Shepler B
Clin Ther
. 2016 Oct;
38(10):2318-2323.
PMID: 27692637
Purpose: The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature. Methods:...
14.
Carson C, Al-Makki A, Shepler B
J Pharm Pharm Sci
. 2016 Apr;
19(1):1-7.
PMID: 27096690
Purpose: To determine if there is sufficient evidence to recommend the addition of pentoxifylline to standard ACE inhibitor and ARB therapy in chronic kidney disease patients to reduce proteinuria and...
15.
Isreb M, Rifai A, Murad L, Al-Makki A, Al-Saghir F, Sekkarie M
Clin Nephrol
. 2016 Mar;
85(5):281-8.
PMID: 27007869
Background: Conflicts can lead to significant disruption in the care of endstage kidney disease (ESKD) patients. The purpose of this paper is to review the available literature on the care...
16.
Bousher A, Al-Makki A, Sutton J, Shepler B
Clin Ther
. 2014 Dec;
36(12):2082-2093.
PMID: 25450474
Purpose: Sucroferric oxyhydroxide is the newest phosphate binder to receive US Food and Drug Administration approval for patients on dialysis. The purpose of this review is to critically evaluate the...
17.
Al-Makki A, Rifai A, Murad L, Zanabli A, Kayal A, Soudan K, et al.
Avicenna J Med
. 2014 Jul;
4(3):54-7.
PMID: 24982825
No abstract available.